Primary membranous nephropathy (PMN) is the most common cause of primary nephrotic syndrome. In the last few years scientific interest mainly focused on the search for new more effective and safer therapeutic strategies and on the guide to their use based on markers of clinical outcomes and disease activity such as the antibodies to the podocyte-expressed phospholipase A2 receptor (PLA2R). The results of the latest trials with the newest pharmacologic approaches open promising horizons in the treatment of membranous glomerulonephritis. This brief review, following the road paved by the previous treatment options, overviews the new advances in the pharmacologic treatment of MN, which represent the near future of its therapy.
Primary membranous nephropathy and its treatment: Past, present and future
Calo L. A.
2021
Abstract
Primary membranous nephropathy (PMN) is the most common cause of primary nephrotic syndrome. In the last few years scientific interest mainly focused on the search for new more effective and safer therapeutic strategies and on the guide to their use based on markers of clinical outcomes and disease activity such as the antibodies to the podocyte-expressed phospholipase A2 receptor (PLA2R). The results of the latest trials with the newest pharmacologic approaches open promising horizons in the treatment of membranous glomerulonephritis. This brief review, following the road paved by the previous treatment options, overviews the new advances in the pharmacologic treatment of MN, which represent the near future of its therapy.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
